Breast Disease pp 109-113 | Cite as

Lobular Carcinoma In Situ

  • Priscilla McAuliffeEmail author


Lobular carcinoma in situ (LCIS) is a high-risk indicator lesion for and a non-obligate precursor of the development of invasive breast carcinoma. Loss of E-cadherin is the hallmark pathological feature of lobular entities. Effective clinical management of LCIS requires good communication between the radiologist, surgeon, pathologist, and medical oncologist and entails surgical excision, subsequent surveillance, and systemic and surgical strategies to reduce the risk of future invasive cancer.


Lobular carcinoma in situ Tamoxifen LCIS Chemoprevention Raloxifene E-cadherin 


  1. 1.
    Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol. 1941;17(4):491–6.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 1978;42(2):737–69.PubMedGoogle Scholar
  3. 3.
    Karabakhtsian RG, Johnson R, Sumkin J, Dabbs DJ. The clinical significance of lobular neoplasia on breast core biopsy. Am J Surg Pathol. 2007;31(5):717–23.PubMedGoogle Scholar
  4. 4.
    Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. AJR Am J Roentgenol. 2001;176(5):1255–9.PubMedGoogle Scholar
  5. 5.
    Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomark Prev. 2005;14(4):1008–11.Google Scholar
  6. 6.
    Degnim AC, King TA. Surgical management of high-risk breast lesions. Surg Clin North Am. 2013;93(2):329–40.PubMedGoogle Scholar
  7. 7.
    Beute BJ, Kalisher L, Hutter RV. Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features. AJR Am J Roentgenol. 1991;157(2):257–65.PubMedGoogle Scholar
  8. 8.
    Frykberg ER. Lobular carcinoma in situ of the breast. Breast J. 1999;5(5):296–303.PubMedGoogle Scholar
  9. 9.
    Page DL, Kidd TE Jr, Dupont WD, Simpson JF, Rogers LW. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol. 1991;22(12):1232–9.PubMedGoogle Scholar
  10. 10.
    Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and bowel project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100(2):238–44.PubMedGoogle Scholar
  11. 11.
    Abdel-Fatah TM, et al. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 2007;31(3):417–26.PubMedGoogle Scholar
  12. 12.
    Dabbs DJ, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):e1–11.PubMedGoogle Scholar
  13. 13.
    Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33(11):1683–94.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Sneige N, Wang J, Baker BA, Krishnamurthy S, Middleton LP. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod Pathol. 2002;15(10):1044–50.PubMedGoogle Scholar
  15. 15.
    Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am J Surg Pathol. 2008;32(11):1721–6.PubMedGoogle Scholar
  16. 16.
    Hatzfeld M. The p120 family of cell adhesion molecules. Eur J Cell Biol. 2005;84(2–3):205–14.PubMedGoogle Scholar
  17. 17.
    Reynolds AB, Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene. 2004;23(48):7947–56.PubMedGoogle Scholar
  18. 18.
    Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, et al. Beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol. 2011;24(2):209–31.PubMedGoogle Scholar
  19. 19.
    Rakha EA, Patel A, Powe DG, Benhasouna A, Green AR, Lambros MB, et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol. 2010;34(10):1472–9.PubMedGoogle Scholar
  20. 20.
    Lakhani SR, Collins N, Sloane JP, Stratton MR. Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin Mol Pathol. 1995;48(2):M74–8.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. 2010;121(3):575–89.PubMedGoogle Scholar
  22. 22.
    Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006;12(22):6652–62.PubMedGoogle Scholar
  23. 23.
    Simpson PT, Reis-Filho JS, Lambros MB, Jones C, Steele D, Mackay A, et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol. 2008;215(3):231–44.PubMedGoogle Scholar
  24. 24.
    Corben AD, Edelweiss M, Brogi E. Challenges in the interpretation of breast core biopsies. Breast J. 2010;16(Suppl 1):S5–9.PubMedGoogle Scholar
  25. 25.
    Houssami N, Ciatto S, Ellis I, Ambrogetti D. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer. 2007;109(3):487–95.PubMedGoogle Scholar
  26. 26.
    Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge RM. Lobular neoplasia on core-needle biopsy–clinical significance. Cancer. 2004;101(2):242–50.PubMedGoogle Scholar
  27. 27.
    Hussain M, Cunnick GH. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–a review. Eur J Surg Oncol. 2011;37(4):279–89.PubMedGoogle Scholar
  28. 28.
    Ottesen GL, Graversen HP, Blichert-Toft M, Christensen IJ, Andersen JA. Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat. 2000;62(3):197–210.PubMedGoogle Scholar
  29. 29.
    Ciocca RM, Li T, Freedman GM, Morrow M. Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Ann Surg Oncol. 2008;15(8):2263–71.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Portschy PR, Marmor S, Nzara R, Virnig BA, Tuttle TM. Trends in incidence and management of lobular carcinoma in situ: a population-based analysis. Ann Surg Oncol. 2013;20(10):3240–6.PubMedGoogle Scholar
  31. 31.
    Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;11:CD002748.Google Scholar
  32. 32.
    Frost MH, Hoskin TL, Hartmann LC, Degnim AC, Johnson JL, Boughey JC. Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol. 2011;18(11):3110–6.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Peled AW, Duralde E, Foster RD, Fiscalini AS, Esserman LJ, Hwang ES, et al. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction. Ann Plast Surg. 2014;72(Suppl 1):S48–52.PubMedGoogle Scholar
  34. 34.
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90(18):1371–88.PubMedGoogle Scholar
  35. 35.
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727–41.PubMedGoogle Scholar
  36. 36.
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696–706.Google Scholar
  37. 37.
    Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394–404.PubMedPubMedCentralGoogle Scholar
  38. 38.
    King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, et al. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat. 2013;142(2):445–53.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Surgery, Division of Surgical OncologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Magee-Women’s Surgical AssociatesPittsburghUSA
  3. 3.Women’s Cancer Research Center of UPMC Hillman Cancer CenterPittsburghUSA

Personalised recommendations